Your browser is old and is not supported. Upgrade for better security.

Invest in TTC Oncology

TTC Oncology developed TTC-352, a small molecule to fight breast cancer

Highlights

1
Novel mechanism of action therapy for hormone resistant of breast cancer.
2
Intellectual property protected until 2033.
3
Safe and well tolerated oral capsule therapy.
4
Biomarker that identifies breast cancer that will respond well to TTC-352.
5
Completed first in human clinical trial.

Our Team

I am medical oncologist (cancer specialist), and I treat breast cancer. I have recognized that I need to have safer, better tolerated, and more effective therapies for breast cancer. In 2013 I have reached out to chemist, Dr Greg Thatcher, to see if he can help. That led to development of TTC-352 capsule.

Pitch


Downloads

Overview